Literature DB >> 11999950

Radiofrequency ablation of early-stage invasive breast tumors: an overview.

S Eva Singletary1, Bruno D Fornage, Nour Sneige, Merrick I Ross, Rache Simmons, Armando Giuliano, Nora Hansen, Henr M Kuerer, Lisa A Newman, Frederick C Ames, Gildy Babiera, Funda Meric, Kelly K Hunt, Beth Edeiken, Attiqa N Mirza.   

Abstract

As the management of breast cancer evolves toward less invasive treatments, the next step is the possibility of removing the primary tumor without surgery. The most promising of the noninvasive ablation techniques is radiofrequency ablation, which uses frictional heating that is caused when ions in the tissue attempt to follow the changing directions of a high-frequency alternating current. Three pilot studies, including an ongoing study at M.D. Anderson Cancer Center, have demonstrated that radiofrequency ablation is effective for the destruction of small primary breast cancers. The most important factorfor successful radiofrequency ablation is accuracy of the ultrasound evaluation, which is used to estimate tumor size, localize the tumor for treatment, and monitor the progress of the ablation. A study in preparation at M.D. Anderson will determine whether the use of radiofrequency ablation alone for the local treatment of primary breast cancer will result in outcomes equivalent to those obtained with breast conservation therapy.

Entities:  

Mesh:

Year:  2002        PMID: 11999950     DOI: 10.1097/00130404-200203000-00011

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  7 in total

1.  Induction of specific cellular and humoral responses against renal cell carcinoma after combination therapy with cryoablation and granulocyte-macrophage colony stimulating factor: a pilot study.

Authors:  Archana Thakur; Peter Littrup; Elyse N Paul; Barbara Adam; Lance K Heilbrun; Lawrence G Lum
Journal:  J Immunother       Date:  2011-06       Impact factor: 4.456

2.  Feasibility of percutaneous excision followed by ablation for local control in breast cancer.

Authors:  V Suzanne Klimberg; Cristiano Boneti; Laura L Adkins; Maureen Smith; Eric Siegel; Vladimir Zharov; Scott Ferguson; Ronda Henry-Tillman; Brian Badgwell; Soheila Korourian
Journal:  Ann Surg Oncol       Date:  2011-09-09       Impact factor: 5.344

3.  Treatment of breast cancer through the application of irreversible electroporation using a novel minimally invasive single needle electrode.

Authors:  Robert E Neal; Ravi Singh; Heather C Hatcher; Nancy D Kock; Suzy V Torti; Rafael V Davalos
Journal:  Breast Cancer Res Treat       Date:  2010-02-27       Impact factor: 4.872

4.  A Phase II Trial Exploring the Success of Cryoablation Therapy in the Treatment of Invasive Breast Carcinoma: Results from ACOSOG (Alliance) Z1072.

Authors:  Rache M Simmons; Karla V Ballman; Charles Cox; Ned Carp; Jennifer Sabol; Rosa F Hwang; Deanna Attai; Michael Sabel; David Nathanson; Andrew Kenler; Linsey Gold; Cary Kaufman; Linda Han; Aaron Bleznak; J Stanley Smith; Dennis Holmes; Bruno Fornage; Carisa Le-Petross; Syed Hoda; Linda McCall; Kelly K Hunt
Journal:  Ann Surg Oncol       Date:  2016-05-24       Impact factor: 5.344

5.  Towards a teleoperated needle driver robot with haptic feedback for RFA of breast tumors under continuous MRI.

Authors:  Rebecca Kokes; Kevin Lister; Rao Gullapalli; Bao Zhang; Alan MacMillan; Howard Richard; Jaydev P Desai
Journal:  Med Image Anal       Date:  2009-02-20       Impact factor: 8.545

6.  Modeling the positioning of single needle electrodes for the treatment of breast cancer in a clinical case.

Authors:  Agnese Denzi; Lidia Strigari; Franco Di Filippo; Claudio Botti; Simona Di Filippo; Letizia Perracchio; Mattia Ronchetti; Ruggero Cadossi; Micaela Liberti
Journal:  Biomed Eng Online       Date:  2015-08-27       Impact factor: 2.819

7.  The Electrode Modality Development in Pulsed Electric Field Treatment Facilitates Biocellular Mechanism Study and Improves Cancer Ablation Efficacy.

Authors:  Chao Cen; Xinhua Chen
Journal:  J Healthc Eng       Date:  2017-05-07       Impact factor: 2.682

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.